Florencia Linero is a lead scientist specializing in Cell and Molecular Biology at Anabiotec, part of the integrated Anacura life sciences ecosystem. With a strong foundation in molecular biology, virology, and translational research, Florencia brings extensive expertise in managing complex analytical platforms and preclinical workflows. Before entering the industry sector, she had a distinguished academic and research career, including a PhD focused on Virology, a postdoctoral fellowship at Ghent University, and receiving the prestigious L'Oréal-UNESCO "For Women in Science" award for her innovative therapeutic work using nanoantibodies. Today, she leverages her deep scientific background to lead advanced analytical and bioinformatic pipelines—bridging the gap between early discovery and cGMP/GCLP-compliant solutions to accelerate drug development.
Presentation: From Early Discovery to Commercialization: Anacura, an Integrated Ecosystem for Accelerating Life Science Innovation
Bringing novel therapeutics from early discovery to commercialization requires navigating fragmented workflows, strict regulatory compliance, and complex analytical hurdles. We introduce an integrated life science ecosystem designed to turn rigorous analytical data into actionable insights across the entire drug development lifecycle. Built on 25+ years of expertise, our interplay of specialized units—spanning preclinical biology, advanced multi-omics and GMP/GCLP-compliant analytical testing—accelerates your path to the clinic and market. Highlighting several of our case examples, we illustrate how our platform synergies optimize drug development pipelines. Here we demonstrate how our preclinical biology can support molecular indication matching to therapeutic Mechanisms of Action (MoA) through in vitro cell line panels coupled with transcriptomics. Moreover, we illustrate how our platform can handle next-generation therapeutics, self-amplifying mRNA vaccine translation and regulatory quality control featuring Critical Quality Attribute (CQA) testing alongside predictive and forced degradation stability platforms using state-of-the-art mass spectrometry. Ultimately, we apply our clinical, analytical, preclinical and bioinformatic workflow to mitigates risk, to ensure regulatory compliance, and to accelerates science into validated therapeutic solutions.
| Contact | Connect | ||||
| Veerstraat 37 1211 HJ Hilversum Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
| Register now | |||
© Copyright 2023 by Hyphen Projects | All rights reserved |